Smart pills could boost med adherence in alcohol liver disease
NCT ID NCT07553377
First seen May 11, 2026 · Last updated May 11, 2026
Summary
This study tests a digital pill system that tracks when medication is taken and provides personalized support based on cognitive behavioral therapy. The goal is to help 50 adults with alcohol use disorder and alcohol-related liver disease stick to their acamprosate regimen. Researchers will measure how feasible and acceptable the system is, and whether it reduces heavy drinking.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.